Long-term cenobamate retention, efficacy, and safety: outcomes from Expanded Access Programme.
Anetta Lasek-BalBarbara KściukTomasz ZielińskiAgnieszka Krzak-KubicaJacek KowalskiBarbara Żorniak-MilachKatarzyna MaciejowskaMaciej MaciejowskiAnna Wagner-KuszMagdalena BosakPublished in: Neurologia i neurochirurgia polska (2023)
Long-term effectiveness, including ≥ 50% seizure reduction and a 100% retention rate, was sustained over 41 months of CNB treatment within the Expanded Access Programme. No new safety issues were identified. These results provide support for the potential long-term clinical benefits of cenobamate.